

**Next**

# Dexa scan report interpretation



**BODY COMP**




Normal Bone Mineral Density ( $> -1.0$ )

Osteopenia (-1.0 to -2.5)

Osteoporosis ( $< -2.5$ )

Carlsbad Imaging Center  
6010 Hidden Valley Road Suite 125  
Carlsbad, CA 92011



1 = Statistically 64% of repeat scans fall within 1SD ( $\pm 0.610 \text{ g/cm}^2$  for AP Spine L1-L4); ( $\pm 0.010 \text{ g/cm}^2$  for DualFemur Total)


2 = NHANES (ages 20-60) / USPNSH (20-40) Average Reference Population (v107); NHANES (ages 20-30) / USPNSH (ages 20-40) Femur Reference Population (v107)

3 = Age and Sex matched for Height, Weight (Females 26-120 kg, Males 30-140 kg), DualFemur Matched for Age, Weight (Females 25-100 kg), Ethnic

7 = DualFemur Total Mean T-Score difference is 0.2, Asymmetry is none

11 = World Health Organization - Definition of Osteoporosis and Osteopenia for Caucasian Women: Normal = T-Score at or above -1.0 SD; Osteopenia = T-Score between -1.0 and -2.5 SD; Osteoporosis = T-Score at or below -2.5 SD; (WHO definitions only apply when a young healthy Caucasian Women reference database is used to determine T-Scores.)

Printed: 11/11/2015 2:23:55 PM (10.50); Patient: 116; mod:655; ph: AP Spine; 21.1;%Fat=24.4%; Scan Mode: Standard; OneScan = 37.0 µGy; Right Femur: 16.3;%Fat=31.7%; Neck Angle (deg)= 57; Scan Mode: Standard = 37.0 µGy; Left Femur: 15.5;%Fat=31.5%; Neck Angle (deg)= 53; Scan Mode: Standard = 37.0 µGy



How to interpret a dxa scan. How to interpret a bone density report.

1. Cummings s R, Melton L J. Epidemiology and results of osteoporotic fractures. Lancet 2002;359:1761-1767. [PubMed] [Google Scholar] 2. Kanis J a, Black D, Cooper C ET to a new approach to the development of evaluation guidelines for osteoporosis. Osteoporos int 2002;13:527-536. [PubMed] [Google Scholar] 3. Johansen A, Evans R J, Stone M D et Al Fracture Incidence In England and Wales: A Study Based on the Population of Cardiff. Lesion 1997;28:655-660. [PubMed] [Google Scholar] 4. Johansen A, Stone M. The cost of treatment of osteoporotic fractures in the female population of the United Kingdom [Letter]. Osteoporos int 2000;11:551. [PubMed] [Google Scholar] 5. Dolan P, Torgerson D J. The cost of treatment of osteoporotic fractures in the female population of the United Kingdom. Osteoporos int 1998;8:611-617. [PubMed] [Google Scholar] 6. MELTON L J, GABRIELS E, CROWSON C S. ET AL COST "Equivalence of Different Osteoporotic Fractures. Osteoporos int 2003;14:383-388. [PubMed] [Google Scholar] 7. Cooper C, Atkinson e J, Jacobs S J. ET to the study of survival based on the population after osteoporotic fractures. AM J Epidemiol 1993;137:1001 à € 1005. [PubMed] [Google Scholar] 8. Center J R, Nguyen T V, Schneider d.e.t a mortality after all the main types of osteoporotic fractures in men and women: an observational study. Lancet 1999;353:878 à € 882. [PubMed] [Google Scholar] 9. Torgerson D J, Dolan P. The cost of treatment of osteoporotic fractures in the female population of the United Kingdom [Letter]. Osteoporos int 2000;11:511 à € 512. [Google Scholar] 10. Clark S. Osteoporosis à € "21st century illness? Lancet 2002;359:1714 [PubMed] [Google Scholar] 11. Genant H K, Engelke K, Forest T.e.t Al Noninvasive Assessment of Bone Mineral and Structure: State of the Art. J Bone Mine Res 1996;11:707-730. [PubMed] [Google Scholar] 12. Storm T, Thamsborg G, Steiniche L.E.T to the effect of intermittent cllical therapy Bone and fracture rate in women with postmenopausal. N Engl J Med 1990;322:1265-1271. 1990;322:1265-1271. [Google Scholar] 13. EvaluaciA'n de la riego de fractura por la OrganizaciA'n Mundial de la Salud y su aplicaciA'n para la deteccA'n de osteoporosis postmenopA'sica serie de informes TA@cnico 843. Ginebra: OMS, 1994 [PubMed] 14. Kanis J A, Ghler C C, for the Committee of Scientific Advisors, International Osteoporosis Foundation Una actualizaciA'n sobre el diagnostico y evaluacion de la osteoporosis con densitometria. Osteoporos Int 2000;11:924-9202. [PubMed] [Google Scholar] 15. Negro D M, Cummings S R, Karf D B.e.t al Prueba aleatoria del efecto del alendronato en riesgo de fractura en mujeres con fracturas vertebrales existentes. Lancet 1998;280:2077-2082. [PubMed] [Google Scholar] 16. Cummings S R, Black D M, Thompson D.E.e.t al Effect of alendronate on risk of fracture in women with low bone resistance but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-2082. [PubMed] [Google Scholar] 17. Harris S T, Watts N B, Genant H K.e.t al Efectos del tratamiento del risedronato sobre fracturas vertebrales y no vertebrales en mujeres con osteoporosis. JAMA 1999;282:1344-1352. [PubMed] [Google Scholar] 18. McClung M R, Genant P, Miller P D.e.t al Efecto del tratamiento del risedronato en riesgo de fractura de cadera en mujeres de edad avanzada. N Engl J Med 2001;343:333-340. [PubMed] [Google Scholar] 19. Cheung Y B, Shih A, Chiu C. Central Effects of the bisphosphonates on disuse atrophy and remodeling in rat models of osteoporosis postmenopA'sica. J Bone Miner Res 2001;16:2413-2419. [PubMed] [Google Scholar] 20. Black D M, Blum S, Cauley J.e.t al Effect of iminidiA'n of bisphosphonate on trabecular bone mineral density in postmenopausal women. J Bone Miner Res 2002;17:131-136. [PubMed] [Google Scholar] 21. Etienne J, Black D M, Millak B.H.e.t al Reduction in the risk of fractures in postmenopausal women with osteoporosis with raloxifene: results of a 3-year randomized clinical trial. JAMA 1999;282:637-645. [PubMed] [Google Scholar] 22. NEER R M, ARNAUD C D, ZANCHETTA J R.e.t al Effect of recombinant human parathyroid hormone (1-34) Fragment on spine and spine fractures, and bone mineral density in postmenopausal osteoporosis. N Engl J MED 2004;350:450-460. [PubMed] [Google Scholar] 23. Seeman E, Ghler C C, Seeman E, Delmas P, Burckhardt P, on behalf of the European Foundation of Osteoporosis and ET AL Bone Diseases Guidelines for the diagnosis and treatment of osteoporosis. Osteoporos int 1997;7:390-406. [PubMed] [Google Scholar] 27. Royal College of Missianic Clinical guidelines for the prevention and treatment of osteoporosis LONDRES: RCP, 1992. 28. Marshall D, Johnell O, Wedel H. Metal analysis of the shape of bone mineral density measures predicts the appearance of osteoporotic fractures. BMJ 1996;312:1254-1259. [PubMed] [Google Scholar] 29. Stone K L, Seeman E, Delmas P, Burckhardt P, on behalf of the European Foundation of Osteoporosis and ET AL Bone Diseases Guidelines for the diagnosis and treatment of osteoporosis. Osteoporos int 2005;20:1185-1194. [PubMed] [Google Scholar] 30. Johnell O, Oden A.e.t al BMD on multiple sites and risk of fracture of multiple types: long-term results of osteoporotic fractures. J Bone Miner Res 2003;18:1947-1954. [PubMed] [Google Scholar] 31. Fogelman I, Blake G M. Different approaches to sea densitometry. J Nucl Med 2002;43:2015-2025. [PubMed] [Google Scholar] 32. GLUE C C C. Monitoring of skeletal change by radiological techniques. J Bone Miner Res 1999;14: 952-1962. [PubMed] [Google Scholar] 33. Fogelman I, Blake G M. Different approaches to sea densitometry. J Nucl Med 2002;43:2015-2025. [PubMed] [Google Scholar] 34. Guglielmi G, Lang T F. Quantitative computed tomography. Sowing Musculoskeletal Radiol 20 026 2194250. [PubMed] [Google Scholar] 35. Lang T F, Guglielmi G, Van Kuijk C.e.t al Medicine of mineral density spine spins and proximal femur by volumetric computed tomography and dual energy X-ray absorption in elderly women with and without vertebral fractures them Bone 200 230 2474250. [PubMed] [Google Scholar] 36. GLUE C C C. Monitoring of skeletal change by radiological techniques. J Bone Miner Res 2003;18:1947-1954. [PubMed] [Google Scholar] 37. Stewart A, Reid D M. Quantitative ultrasound in osteoporosis. Sowing Musculoskeletal Radiol 20 026 2194250. [PubMed] [Google Scholar] 38. Stewart A, Reid D M. Quantitative ultrasound in osteoporosis. Sowing Musculoskeletal Radiol 20 026 2194250. [PubMed] [Google Scholar] 39. Faulkner K G, Von Stettton E, Miller P. Discordance in patient classification using T-scores. J Clin Densitom 19 992 343-350. [PubMed] [Google Scholar] 40. Blake G M, Fogelman I, Broadband ultrasound attenuation predicts fractures strongly and regardless of densitometry in older women. Arch Intern Med 1997;157:629-634. [PubMed] [Google Scholar] 41. Cummings S R, Black D M, Nevitt M C.e.t al Bone density at several sites for the prediction of hip fractures. Bone 2 001 483:96. [PubMed] [Google Scholar] 42. Black D M, Palermo L, Bauer D. How well does mass predict long-term risk of hip fracture? Osteoporos Int 200 011 (Suppl 2) S59 [Google Scholar] 43. Orwoll E S, Marshall L M, Chan B M. BMD on various sites for the prediction of hip fracture: a meta-analysis. J Bone Miner Res 2000;15(Supl 2):S145 [Google Scholar] 44. Hane D, Dargent-Molina P, Schott A.M et al Ultrasoundographic heel measurements to predict his fracture in elderly women: the EPIDOS prospective study. Osteoporos Int 1999;9:550-556. [PubMed] [Google Scholar] 45. Blake G M, Patel R, Knapp K M.e.t al Is the combination of two DMO measurements improves fracture discrimination? J Bone Miner Res 2003;18:1955-1963. [PubMed] [Google Scholar] 46. Johansson H, Oden A, Johnell O.e.t al To Optimize the measurements of the DMO to identify high-risk groups for the treatment à la test analysis. J Bone Miner Res 2004;19:906-913. [PubMed] [Google Scholar] 47. Johnell O, Oden A, Johnell O.e.t al The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001;12:417a à 427. [PubMed] [Google Scholar] 48. Borgstrom F, Johnell O, Kanis J A, Oden A, Johnell O.e.t al At what risk of hip fracture is profitable to treat? Umbrales of international intervention for the treatment of osteoporosis. Osteoporos Int 2006;17:1459 à 1471. [PubMed] [Google Scholar] 49. Kanis J A, Borgstrom F, Zethraeus N.e.al Umbrales of intervention for osteoporosis in the United Kingdom. Hueso 2005;6224 à 62. [PubMed] [Google Scholar] 50. Blake G M, Patel R, Knapp K M.e.t al Is the combination of two DMO measurements improves fracture discrimination? J Bone Miner Res 2003;18:1955-1963. [PubMed] [Google Scholar] 51. Baedke R, Below A, Fraser W D.e.t al Can peripheral measurements of DXA be used to predict fractures in older women living in the community? Osteoporos Int 2005;16:1177-1183. [PubMed] [Google Scholar] 52. Viewer A C, Wahner H W, Dunn W L.e.t to Updated Data on Proximal Adult Femur Mineral Levels. Osteoporos Int 2001;16(Supl 1)S166 [PubMed] [Google Scholar] 53. Faulkner K G, Roberts L A, McCullough M. Discrepancies in policy data between Lunar and Hologic DDXAosteoporosis Int 1996;64:32-436. [PubMed] [Google] [Hanson J. Normalization of femur BMD. J Bone Miner Res 1997 121 3164:137. [PubMed] [Google Scholar] 55. Blake G M, Chin D J, Steel S A.e.t al A list of device-specific thresholds for the clinical interpretation of peripheral X-ray absorption tests. Osteoporos Int 200 2:51 929-1936. [PubMed] [Google Scholar] 56. International Society of Clinical Densitometry Official positions of the International Society of Clinical Densitometry: updated 2005. (accessed March 26, 2007) 57. Kanis J A. Diagnosis of osteoporosis and evaluation of the risk of fracture. Lancet 20 023 591 929-1936. [PubMed] [Google Scholar] 58. Kanis J A, Borgstrom F, De Laet C.e.t al Assessment of fracture risk. Osteoporos Int 200 516 581:589. [PubMed] [Google Scholar] 59. De Laet C, Oden A, Johnell O.e.t al The impact of the use of multiple risk factors for fracture on case determination strategies: a mathematical approach. Osteoporos Int 200 516 581 313-318. [PubMed] [Google Scholar] 60. Kanis J A, Johnell O, Oden A.e.t al Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 200 112 989:495. [PubMed] [Google Scholar] 61. Kanis J A, Johnell O, De Laet C.e.t to anterior fracture metaanalysis and risk of posterior fracture. Bone 200 435 375:382. [PubMed] [Google Scholar] 62. Kanis J A, Johansson H, Oden A.e.t al A meta-analysis of previous uses of corticosteroids and risk of fracture. J Bone Miner Res 200 409 893-899. [PubMed] [Google Scholar] 63. Kanis J A, Johansson H, Oden A.e.t al Family history of fracture and risk of fracture: a meta-analysis. BMJ 1996;312:1254-1259. [PubMed] [Google Scholar] 64. Kanis J A, Johnell O, Oden A.e.t al Smoking and fracture risk: a meta-analysis. Bone 200 004 351 029-1037. [PubMed] [Google Scholar] 65. Blake G M, Patel R, Knapp K M.e.t al Is the combination of two DMO measurements improves fracture discrimination? J Bone Miner Res 2003;18:1955-1963. [PubMed] [Google Scholar] 66. Johnell O, Oden A, Johnell O.e.t al To Optimize the measurements of the DMO to identify high-risk groups for the treatment à la test analysis. J Bone Miner Res 2004;19:906-913. [PubMed] [Google Scholar] 67. Johnell O, Oden A, Johnell O.e.t al The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001;12:417a à 427. [PubMed] [Google Scholar] 68. Blake G M, Patel R, Knapp K M.e.t al Is the combination of two DMO measurements improves fracture discrimination? J Bone Miner Res 2003;18:1955-1963. [PubMed] [Google Scholar] 69. Johnell O, Oden A, Johnell O.e.t al To Optimize the measurements of the DMO to identify high-risk groups for the treatment à la test analysis. J Bone Miner Res 2004;19:906-913. [PubMed] [Google Scholar] 70. Blake G M, Patel R, Knapp K M.e.t al Is the combination of two DMO measurements improves fracture discrimination? J Bone Miner Res 2003;18:1955-1963. [PubMed] [Google Scholar] 71. Johnell O, Oden A, Johnell O.e.t al The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001;12:417a à 427. [PubMed] [Google Scholar] 72. Kanis J A, Borgstrom F, Zethraeus N.e.al Umbrales of intervention for osteoporosis in the United Kingdom. Hueso 2005;6224 à 62. [PubMed] [Google Scholar] 73. Zethraeus N, Borgstrom F, Strom O.e.t al Costa à effectiveness he treatment and prevention of osteoporosis à la literature review and a reference model. Osteoporos Int 2007;17:189a à 193d. [PubMed] [Google Scholar] 74. Kanis J A, Borgstrom F, Johnell O.e.t al Costa à effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 2005;16:151 à 153. [PubMed] [Google Scholar] 75. Borgstrom F, Carsson A, Sintonen H.e.al Costa à effectiveness risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int 2006;17:1781-1793. [PubMed] [Google Scholar] 76. National Institute of Health and Clinical Excellence Osteoporosis: Evaluation of the risk of fracture and prevention of osteoporotic fractures in older women: the National Osteoporosis Risk Assessment. J Bone Miner Res 2002;17:22-230. [PubMed] [Google Scholar] 77. National Institute of Health and Clinical Excellence Osteoporosis: Evidence of the National Osteoporosis Risk Assessment. J Bone Miner Res 2002;17:22-230. [PubMed] [Google Scholar] 78. National Institute of Health and Clinical Excellence Osteoporosis: EPIC-Prospective population study. Lancet 2004;363:197-202. [PubMed] [Google Scholar] 79. Miller P D, Siris E S, Barrett Connor E.e.t to Prediction of the Risk of Fracture in Postmenopausal White Women with Peripheral Bone Densitometry: Evidence of the National Osteoporosis Risk Assessment. J Bone Miner Res 2002;17:22-230. [PubMed] [Google Scholar] 80. Blake G M, Patel R, Knapp K M.e.t al Is the combination of two DMO measurements improves fracture discrimination? J Bone Miner Res 2003;18:1955-1963. [PubMed] [Google Scholar] 81. National Institute of Health and Clinical Excellence Efficiency Clinic and the profitability of the effectiveness of technologies for the primary prevention of osteoporotic fragility fractures in postmenopausal women. . Etdronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the primary prevention of osteoporotic fragility in postmenopausal women. . Etidronate, Risedronate, Raloxifene, Strontium and Teriparatide Reneate for the secondary prevention of osteoporotic fragility in postmenopausal